Physician profile
Leigh Lewis
NPI 1083698625
$1,778.96
in general payments reported to CMS, 2019-2025
28 companies · $417 in 2025
The $417 reported for 2025 was more than what 76% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $130 · 2020: $46.06 · 2021: $70.08 · 2022: $357 · 2023: $449 · 2024: $310 · 2025: $417.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,176.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,175.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $295.18 | 2019-2025 | |
| Mayne Pharma Commercial LLC | $284.87 | 2021-2025 | |
| Novo Nordisk INC | $169.57 | 2023-2024 | Wegovy |
| Meditrina | $122.31 | 2025 | |
| Astellas Pharma US INC | $92.40 | 2024-2025 | Veozah |
| Bayer Healthcare Pharmaceuticals INC. | $73.02 | 2022-2024 | |
| Myriad Women'S Health, INC. | $70.86 | 2023 | Myrisk |
| Coopersurgical, INC. | $69.35 | 2020-2025 | Paragard T 380a |
| Biotissue Holdings INC. | $63.21 | 2023 | |
| Exeltis, USA INC. | $57.07 | 2020-2023 | Slynd |
| Biogen, INC. | $49.48 | 2025 | Zurzuvae |
| Hologic Sales and Service, LLC | $48.44 | 2019-2024 | Aptima, Thinprep 2000 Processor |
| Shield Therapeutics INC | $40.26 | 2024 | |
| Agile Therapeutics, INC. | $39.96 | 2022-2023 | Twirla |
| Myovant Sciences INC. | $38.97 | 2022 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mylan Pharmaceuticals INC. | $37.10 | 2019-2021 | |
| Pfizer INC. | $34.26 | 2023-2024 | |
| Scynexis, INC. | $23.98 | 2022 | |
| Avion Pharmaceuticals | $20.87 | 2023 | Balcoltra |
| Axonics, INC. | $19.24 | 2020 | |
| Merck Sharp & Dohme LLC | $18.81 | 2019 | |
| Abbott Laboratories | $18.41 | 2023 | Freestyle Libre 3 |
| Sumitomo Pharma America, INC. | $16.82 | 2023 | Myfembree |
| Urovant Sciences INC | $16.63 | 2022 | |
| Amgen INC. | $15.90 | 2025 | Evenity |
| Mycovia Pharmaceuticals, INC. | $15.46 | 2022 | |
| Renovia INC | $14.07 | 2021 | |
| Therapeuticsmd, INC. | $12.46 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Leigh Lewis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.